Case report: An occult hepatitis B virus infection reactivation in an HIV/HCV coinfected patient during an immune reconstitution inflammatory syndrome.
Humans
Hepatitis B virus
/ physiology
Hepatitis B, Chronic
Antiviral Agents
/ therapeutic use
Coinfection
/ drug therapy
Immune Reconstitution Inflammatory Syndrome
/ diagnosis
HIV Infections
/ complications
Symptom Flare Up
Hepatitis C, Chronic
/ drug therapy
Hepatitis B
/ complications
DNA, Viral
/ genetics
HBV/HIV coinfection
hepatitis B virus
immune reconstitution inflammatory syndrome (IRIS)
occult HBV
reactivation
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
01
2023
accepted:
24
03
2023
medline:
2
5
2023
pubmed:
1
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
The natural history of occult hepatitis B virus infection (OBI) and the mechanism involved in HBV reactivation are only partially understood. As regards people living with HIV (PLWH), HBV reactivation is estimated to occur with an incidence ratio of 0.019 cases per 100 person-year. Here we report the case of OBI reactivation in a HIV/HCV co-infected patient followed for 25 years at our Infectious Diseases Unit, but, unfortunately, lost to follow-up about 19 months after Direct-acting antivirals (DAAs) treatment. At re-engagement, blood tests showed high replication of plasmatic HIV-RNA along with severe immunosuppression and normal levels of liver enzymes. However, 3 months after ART reintroduction, an immune reconstitution inflammatory syndrome (IRIS) was diagnosed with high detectable HBV-DNA load and transaminase elevation. Our case report shows how the balance between the virus and the host immune system is quite a dynamic process that might significantly impact the course of the disease. The aim of this case report is to bring to the attention of physicians that, although OBI reactivation is a rather rare occurrence, even amongst PLWH, its potential consequences compel to a high alertness on the matter. Therefore, especially in patients with an impaired immune system and on a tenofovir or lamivudine-sparing regimen, HBV serological and virological markers should always be strictly monitored, even in the absence of a hepatitis flare.
Identifiants
pubmed: 37124041
doi: 10.3389/fcimb.2023.1143346
pmc: PMC10145166
doi:
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143346Informations de copyright
Copyright © 2023 Zaltron, Cambianica, Di Gregorio, Colangelo, Storti, Tiecco, Castelli and Quiros-Roldan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Gut Liver. 2023 Mar 15;17(2):288-298
pubmed: 36268584
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-180
pubmed: 29371017
J Int Assoc Provid AIDS Care. 2015 Jul-Aug;14(4):360-8
pubmed: 25999329
World J Clin Cases. 2022 Jun 16;10(17):5518-5530
pubmed: 35979101
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829
pubmed: 35738290
Front Immunol. 2019 Sep 20;10:2240
pubmed: 31620140
Open Forum Infect Dis. 2022 Aug 29;9(9):ofac451
pubmed: 36092833
J Virol. 1993 Oct;67(10):5823-32
pubmed: 8396658
J Virol. 2003 Jan;77(1):68-76
pubmed: 12477811
Sci Rep. 2020 Oct 13;10(1):17066
pubmed: 33051567
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
Front Microbiol. 2022 Apr 07;13:850665
pubmed: 35464946
Clin Infect Dis. 2013 Feb;56(4):606-12
pubmed: 23090927
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):798-802
pubmed: 20080755
Curr HIV/AIDS Rep. 2018 Apr;15(2):172-181
pubmed: 29572624
Gastroenterology. 2015 Jan;148(1):221-244.e3
pubmed: 25447852
Lancet Gastroenterol Hepatol. 2022 Oct;7(10):932-942
pubmed: 35961359
Braz J Infect Dis. 2016 Jul-Aug;20(4):330-4
pubmed: 26748234
Front Immunol. 2021 Nov 25;12:775461
pubmed: 34899733
Cells. 2021 May 06;10(5):
pubmed: 34066322
Clin Med (Lond). 2018 Jun;18(3):212-218
pubmed: 29858430
Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1403-1407
pubmed: 30969194
AIDS. 2021 Aug 1;35(10):1707-1708
pubmed: 34270493
J Infect Dis. 2021 Jun 15;223(12):2080-2089
pubmed: 33073291
Hepatology. 2005 Apr;41(4):826-31
pubmed: 15726541
World J Clin Cases. 2021 Jul 26;9(21):5769-5781
pubmed: 34368296
J Hepatol. 2022 Dec;77(6):1670-1689
pubmed: 35850281
AIDS. 2007 Mar 30;21(6):771-4
pubmed: 17413702
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875